Longeveron Inc. announced key leadership updates, with Than Powell appointed as interim CEO and Dr. Joshua Hare as Executive Chairman of the Board.
Wa'el Hashad stepped down as CEO and Board member, leading to a national search for a permanent CEO.
The company has a robust pipeline focusing on laromestrocel stem cell therapy for life-threatening conditions.
Leadership Changes
Than Powell appointed as interim CEO and Dr. Hare as Executive Chairman after Wa'el Hashad's resignation.
Pipeline Update
Positive outcomes in laromestrocel clinical trials with anticipation of top-line results in 2026.
Strategic Search
National search planned for a permanent CEO to lead the company's future success.
- Longeveron's focus on stem cell therapy positions them at the forefront of medical innovation in treating life-threatening conditions.
- The leadership changes aim to ensure the continued progress and success of the laromestrocel therapy pipeline.
With a strong leadership team in place and promising clinical trial results, Longeveron is poised for significant advancements in stem cell therapy and patient care.